Affiliations 

  • 1 Department of Pharmacology, P.I.M.S RMC Loni, Ahmednagar, Maharashtra, India
  • 2 Department of Clinical Biochemistry, P.I.M.S RMC Loni, Ahmednagar, Maharashtra, India
  • 3 Ottawa Fertility Centre, Ottawa, Canada
  • 4 Microbiology Unit, AIMST University, Kedah, Malaysia
J Basic Clin Pharm, 2010 Dec;2(1):27-32.
PMID: 24825999

Abstract

Emergence of extensively drug resistant tuberculosis (XDR-TB) has been reported by more than 55 countries. XDR-TB is considered as untreatable and highly fatal disease. In developing countries like India, number of cases of multi-drug resistant tuberculosis (MDR-TB) and XDR-TB are increasing. Emergence of resistance to Isoniazid and Rifampicin, the two most effective and well tolerated agents, coupled with resistance to second line agents pose limited treatment options for XDR-TB. The present minireview provides information about the seriousness of XDR-TB and the drugs available for its treatment. Although considered a fatal disorder, judicious use of combination of drugs, retaining their antimycobacterial activity, can improve the clinical outcome of XDR-TB. Only such an approach can provide some hope for the patients of XDR-TB.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.